They are not going to get approved based on that one study with uneven treatment duration. I suppose they know it, thus my speculation of other intended purpose.
I didn't comment on other points because I don't think they should run trials for approval purpose on their own regardless how good the drug is - it is NOT for small biotech considering even BMY wouldn't do on its own - it is irrelevant to me.
Market Data 
Markets 
AI
